257 related articles for article (PubMed ID: 30476914)
21. Plasma metabolic profiling analysis of cyclophosphamide-induced cardiotoxicity using metabolomics coupled with UPLC/Q-TOF-MS and ROC curve.
Yin J; Xie J; Guo X; Ju L; Li Y; Zhang Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():428-435. PubMed ID: 27649503
[TBL] [Abstract][Full Text] [Related]
22. Metabolomic profiling suggests long chain ceramides and sphingomyelins as a possible diagnostic biomarker of epithelial ovarian cancer.
Kozar N; Kruusmaa K; Bitenc M; Argamasilla R; Adsuar A; Goswami N; Arko D; Takač I
Clin Chim Acta; 2018 Jun; 481():108-114. PubMed ID: 29481776
[TBL] [Abstract][Full Text] [Related]
23. Metabolic profiling of potential lung cancer biomarkers using bronchoalveolar lavage fluid and the integrated direct infusion/ gas chromatography mass spectrometry platform.
Callejón-Leblic B; García-Barrera T; Grávalos-Guzmán J; Pereira-Vega A; Gómez-Ariza JL
J Proteomics; 2016 Aug; 145():197-206. PubMed ID: 27255828
[TBL] [Abstract][Full Text] [Related]
24. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
Huang D; Gaul DA; Nan H; Kim J; Fernández FM
J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
[TBL] [Abstract][Full Text] [Related]
25. Wide spectrum targeted metabolomics identifies potential ovarian cancer biomarkers.
Plewa S; Horała A; Dereziński P; Nowak-Markwitz E; Matysiak J; Kokot ZJ
Life Sci; 2019 Apr; 222():235-244. PubMed ID: 30853626
[TBL] [Abstract][Full Text] [Related]
26. Analysis of metabolites and metabolic pathways in breast cancer in a Korean prospective cohort: the Korean Cancer Prevention Study-II.
Yoo HJ; Kim M; Kim M; Kang M; Jung KJ; Hwang SM; Jee SH; Lee JH
Metabolomics; 2018 Jun; 14(6):85. PubMed ID: 30830383
[TBL] [Abstract][Full Text] [Related]
27. Large-scale profiling of metabolic dysregulation in ovarian cancer.
Ke C; Hou Y; Zhang H; Fan L; Ge T; Guo B; Zhang F; Yang K; Wang J; Lou G; Li K
Int J Cancer; 2015 Feb; 136(3):516-26. PubMed ID: 24895217
[TBL] [Abstract][Full Text] [Related]
28. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
[TBL] [Abstract][Full Text] [Related]
29. Identification of essential hypertension biomarkers in human urine by non-targeted metabolomics based on UPLC-Q-TOF/MS.
Zhao H; Liu Y; Li Z; Song Y; Cai X; Liu Y; Zhang T; Yang L; Li L; Gao S; Li Y; Yu C
Clin Chim Acta; 2018 Nov; 486():192-198. PubMed ID: 30092170
[TBL] [Abstract][Full Text] [Related]
30. Saturated fatty acids as possible important metabolites for epithelial ovarian cancer based on the free and esterified fatty acid profiles determined by GC-MS analysis.
Yin R; Yang T; Su H; Ying L; Liu L; Sun C
Cancer Biomark; 2016 Sep; 17(3):259-269. PubMed ID: 27802202
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of serum metabolites in gestational diabetes mellitus by UPLC/Q-TOF-MS.
Liu T; Li J; Xu F; Wang M; Ding S; Xu H; Dong F
Anal Bioanal Chem; 2016 Feb; 408(4):1125-35. PubMed ID: 26677023
[TBL] [Abstract][Full Text] [Related]
32. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum.
Zhang X; Xu L; Shen J; Cao B; Cheng T; Zhao T; Liu X; Zhang H
Biochim Biophys Acta; 2013 Aug; 1832(8):1207-16. PubMed ID: 23524237
[TBL] [Abstract][Full Text] [Related]
33. Expanded metabolomics approach to profiling endogenous carbohydrates in the serum of ovarian cancer patients.
Cheng Y; Li L; Zhu B; Liu F; Wang Y; Gu X; Yan C
J Sep Sci; 2016 Jan; 39(2):316-23. PubMed ID: 26549419
[TBL] [Abstract][Full Text] [Related]
34. Wide-Targeted Metabolome Analysis Identifies Potential Biomarkers for Prognosis Prediction of Epithelial Ovarian Cancer.
Hishinuma E; Shimada M; Matsukawa N; Saigusa D; Li B; Kudo K; Tsuji K; Shigeta S; Tokunaga H; Kumada K; Komine K; Shirota H; Aoki Y; Motoike IN; Yasuda J; Kinoshita K; Yamamoto M; Koshiba S; Yaegashi N
Toxins (Basel); 2021 Jun; 13(7):. PubMed ID: 34209281
[TBL] [Abstract][Full Text] [Related]
35. Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry.
Li J; Xie H; Li A; Cheng J; Yang K; Wang J; Wang W; Zhang F; Li Z; Dhillon HS; Openkova MS; Zhou X; Li K; Hou Y
Oncotarget; 2017 Jul; 8(29):46834-46845. PubMed ID: 27564116
[TBL] [Abstract][Full Text] [Related]
36. High-throughput ultra-performance liquid chromatography-mass spectrometry characterization of metabolites guided by a bioinformatics program.
Zhang AH; Wang P; Sun H; Yan GL; Han Y; Wang XJ
Mol Biosyst; 2013 Sep; 9(9):2259-65. PubMed ID: 23821129
[TBL] [Abstract][Full Text] [Related]
37. Serum metabolomics profiling and potential biomarkers of myopia using LC-QTOF/MS.
Dai L; Yang W; Qin X; Li Y; Cao H; Zhou C; Wang Y
Exp Eye Res; 2019 Sep; 186():107737. PubMed ID: 31325450
[TBL] [Abstract][Full Text] [Related]
38. LC-MS-based serum metabolomics reveals a distinctive signature in patients with rheumatoid arthritis.
Li J; Che N; Xu L; Zhang Q; Wang Q; Tan W; Zhang M
Clin Rheumatol; 2018 Jun; 37(6):1493-1502. PubMed ID: 29442259
[TBL] [Abstract][Full Text] [Related]
39. Metabolomics study of serum and urine samples reveals metabolic pathways and biomarkers associated with pelvic organ prolapse.
Deng W; Rao J; Chen X; Li D; Zhang Z; Liu D; Liu J; Wang Y; Huang O
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1136():121882. PubMed ID: 31809960
[TBL] [Abstract][Full Text] [Related]
40. Study of the metabolomics characteristics of patients with metabolic syndrome based on liquid chromatography quadrupole time-of-flight mass spectrometry.
Wu N; Wang W; Yi M; Cheng S; Wang D
Ann Endocrinol (Paris); 2018 Feb; 79(1):37-44. PubMed ID: 29246383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
